Mariann Caprino: Novavax

MALVERN, Pa., June 12 — Novavax, Inc. today appointed Mariann Caprino Vice President of Corporate Communications and Investor Relations. A former journalist, Ms. Caprino served for nearly a decade as a spokesperson for Pfizer Inc., where she was Senior Director and Team Leader of corporate media relations. Ms. Caprino will report directly to Novavax President and Chief Executive Officer, Dr. Rahul Singhvi.

“As Novavax continues to evolve and apply our novel vaccine technology to an expanding number of infectious diseases, communications will serve a critical link between the company and its many stakeholders,” Dr. Singhvi said. “We are very pleased to have a communications professional of Ms. Caprino’s background and caliber to join our senior management team.”

Prior to joining Pfizer, Ms. Caprino was a national business writer at The Association Press’s worldwide headquarters in New York City. She also served as Director of Communications at the American Foundation for AIDS Research. At Pfizer, Ms. Caprino was responsible for corporate communications surrounding the company’s portfolio of prescription medicines. She was involved in a number of high-profile launches and issues, including the worldwide introduction of VIAGRA(R) in 1998.

“I am looking forward to working closely with a highly talented senior management team in building Novavax’s future,” Ms. Caprino said. “I am especially excited by the commitment Novavax has made to combating disease with new, innovative and more effective vaccines that will be available to the world at large.”

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company’s technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax’s drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.

Please Support Our Work
Email your friends about us. Subscribe to our paid publication Online IR Trends Quarterly. Get us to recommend improvements to your IR website (we're really good at it).